Rankings / Metabolic Health

Tesofensine

Metabolic Health · Triple monoamine reuptake inhibitor

Tier D+

investigationaldopamineserotonin
3.7 / 10
Tier D+
Ev 3 Bn 6.5 Sf 3.5

Bottom line

Read Off Label grades Tesofensine as D+ (3.7/10) based on weak evidence, med-high benefit magnitude, and a med-high-risk safety profile.

Saniona now developing for hypothalamic obesity (rare disease orphan indication).

Typical use: 0. — Investigational in multiple jurisdictions; not approved.

What this is

Saniona now developing for hypothalamic obesity (rare disease orphan indication). Substantial weight loss in obesity trials. Cognitive trials disappointed. Research chem availability exists; caution with CV effects.

Mechanism

Inhibits DAT, NET, SERT; originally developed by NeuroSearch for Alzheimer's/Parkinson's (failed primary endpoints); repurposed for obesity with striking weight loss effects

Dose & route

0.25-1 mg/day PO in obesity trials

Common questions

Does Tesofensine work?
Read Off Label rates the evidence for Tesofensine as Weak and the benefit magnitude as med-high, producing an overall grade of D+ (3.7/10). Saniona now developing for hypothalamic obesity (rare disease orphan indication).
Is Tesofensine safe?
Tesofensine has a med-high risk profile in published human data. Legal status: Investigational in multiple jurisdictions; not approved. This is not medical advice — see the disclaimer.
What is the typical dose for Tesofensine?
0.25-1 mg/day PO in obesity trials
How does Tesofensine work?
Inhibits DAT, NET, SERT; originally developed by NeuroSearch for Alzheimer's/Parkinson's (failed primary endpoints); repurposed for obesity with striking weight loss effects

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.